The prevalence of major cardiovascular risk factors in the Czech population in 2006-2009. The Czech post-MONICA study;Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech post-MONICA

Cor et Vasa

Volumn 53, Issue 4-5, 2011, Pages 220-229

  Cífková, Renata ^a,b   Bruthans, Jan ^b   Adámková, Věra ^b   Jozífová, Marie ^a,b   Galovcová, Markéta ^b   Wohlfahrt, Peter ^b   Krajčoviechová, Alena ^a,b   Petržílková, Zdena ^b   Lánská, Věra ^b   Poledne, Rudolf ^b   Stávek, Petr ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Blood pressure; BMI; Cardiovascular diseases; Hypertension; Population random sample; Smoking; Total cholesterol

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CZECH REPUBLIC; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; POPULATION RESEARCH; PREVALENCE; RISK FACTOR; SEX DIFFERENCE; SMOKING;

EID: 80053649675     PISSN: 00108650     EISSN: None     Source Type: Journal    
DOI: 10.33678/cor.2011.050     Document Type: Article

References (54)

1. Zemřelí 2009. ÚZIS, ČR, 2010.
2. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231-1248. (Pubitemid 27332143)
3. Müller-Nordhorn J, Binting S, et al. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J 2008;29:1316-1326. (Pubitemid 351768126)
4. rd ed. Brussels: European Heart Network, 2008.
5. WHO MONICA Project Principal Investigators: The World Health Organization MONICA project (Monitoring trends and determinants in cardiovascular disease): A major international collaboration. J Clin Epidemiol 1988;41:105-114.
6. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547-1557. (Pubitemid 29219203)
7. Kannel WB, McGee DL, Gordon T. A general cardiovascular risk profile: The Framingham Study. Am J Cardiol 1976;74:46-51.
8. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-362.
9. Pyörala K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:130-131.
10. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-1503. (Pubitemid 28470470)
11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 02-5215. Circulation 2002;106:3143-3420.
12. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610. (Pubitemid 37012194)
13. Yusuf S, Hawken S, Ôunpuu S, et al and INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004;364:937-952. (Pubitemid 39208455)
14. Graham I, Atar D, Borch-Jonsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardio Prev Rehab 2007;14(Supp 2):S1-S88.
15. Cífková R, Škodová Z, Bruthans J, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010;211:676-681.
16. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. for the WHO MONICA Project. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000;355:675-687. (Pubitemid 30107623)
17. Berghöfer A, Pischon T, Reinhold T, et al. Obesity prevalence from a European perspective. A systematic review. BMC Public Health 2008;8:200.
18. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
19. Seidell JC. Time trends in obesity: An epidemiological perspective. Horm Metab Res 1997;29:155-158. (Pubitemid 27240291)
20. Seidell JC. Obesity in Europe: scaling an epidemic. Int J Obes 1995;19:S1-S4.
21. Flegal KM, Caroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes 1998;22:39-47. (Pubitemid 28036587)
22. Williamson DF, Madans J, Anda RF, et al. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991;324:739-745.
23. Boyle CA, Dobson AJ, Egger C, Magnus P. Can the increasing weight of Australians be explained by the decreasing prevalence of cigarette smoking? Int J Obes 1994;18:55-60. (Pubitemid 24029246)
24. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity impact on cardiovascular disease. Circulation 1998;98:1472-1476.
25. Eckel RH. Obesity and heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997;96:3248-3250. (Pubitemid 27500134)
26. Dengel DR, Galeckim AT, Hagberg JM, Pratley RE. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. Am J Hypertens 1998;11: 1405-1412. (Pubitemid 29030303)
27. Pleis JR, Lucus JW, Ward BW. Summary health statistics for U.S. adults: National Health Interview Survey, 2008. Vital Health Stat 10 2009;(242):1-157.
28. Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998;279:119-124. (Pubitemid 28068301)
29. Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tobacco Control 1994;3:242-247.
30. Molarius A, Parson RW, Dobson AJ, et al. Trends in cigarette smoking in 36 population from the early 1980s to the mid-1990s: Findings from the WHO MONICA project. Am J Public Health 2001;91:206-212. (Pubitemid 32113177)
31. Cífková R, Škodová Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010;28:2196-2203.
32. Elliott P, Stamler J, Nichols R, et al. for the Intersalt Cooperative Research Group et al. Intersalt revisited: further analyses of 24-hour sodium excretion and blood pressure within and across populations. BMJ 1996;312:1249-1253. (Pubitemid 26147660)
33. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? Analysis of data from trials of salt reduction. BMJ 1991;302:819-824.
34. Cutler JA, Follmann D, Alender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997;65:643S-651S. (Pubitemid 27063065)
35. Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996;275:1590-1597. (Pubitemid 26154246)
36. Sacks FM, Svetkey LP, Vollmer WM, et al; for the DASH-sodium collaborative research group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10. (Pubitemid 32064838)
37. Puddey IB, Beilin LJ, Rakic V. Alcohol, hypertension and the cardiovascular system: a critical appraisal. Addiction Biol 1997;2:159-170. (Pubitemid 27183101)
38. Food consumption data released the Czech Statistical Office at: http://www.czso.cz: table 03.02: Food consumption and non-alcoholic beverages in 1989-2007.
39. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-827.
40. Erdine S, Aran SN. Current status of hypertension control around the world. Clin Exp Hypertens 2004;26:731-738. (Pubitemid 40129762)
41. Marques-Vidal P, Tuomilehto J. Hypertension, awareness, treatment and control in the community: is the rule of halves still valid. J Hum Hypertens 1997;11:213-220. (Pubitemid 27270421)
42. Joffres MR, Ghadirian P, Fodor JG, et al. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097-1102. (Pubitemid 27486342)
43. Leenen FH, Dumais J, McInnis NH, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008;178: 1441-1449. (Pubitemid 351775721)
44. Hansson L, Zancheti A, Carruthers SG, et al; on behalf of the HOT Study Group. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998:351: 1755-1762. (Pubitemid 28269185)
45. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300.
46. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002;20:1461-1464. (Pubitemid 34921162)
47. Vartiainen E, Puska P, Pekkanen J, et al. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994;309:23-27. (Pubitemid 24202635)
48. Puska P. The North Karelia Project: From community intervention to national activity in lowering cholesterol levels and CHD risk. Eur Heart J 1999;20:S9-S13. (Pubitemid 29525355)
49. Bruthans J, Cífková R, Lánská V, et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007 (odesláno do tisku).
50. The DECODE study group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and Cardiovascular Mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001:161; 397-404.
51. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
52. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Organization, 1999.
53. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO consultation/IDF Consultation. Geneva, World Health Organization, 2006.
54. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524. (Pubitemid 28172927)